MedPath
Found 1 clinical trials|View Analysis
Sort by:

Mezigdomide and Elranatamab for Relapsed And/or Refractory Multiple Myeloma

Phase 1
Recruiting
Conditions
Relapsed Refractory Multiple Myeloma (RRMM)
Interventions
First Posted Date
2024-10-17
Last Posted Date
2024-12-24
Lead Sponsor
YOUNGIL KOH
Target Recruit Count
75
Registration Number
NCT06645678
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath